Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Cancer

Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXijuan LinLZLiu ZCYChen Yang

Discussion

Loading...

Member takes

Overview

Prospective trial evaluates selinexor's efficacy with azacitidine or ruxolitinib in MDS/MPN patients, implying potential benefits.

Key Points

  • This study aims to assess the effectiveness of selinexor in combination with azacitidine or ruxolitinib for treating myelodysplastic/myeloproliferative neoplasm overlap syndromes.
  • Conducted as a prospective, single-arm trial
  • Evaluated patients with MDS/MPN receiving selinexor with either azacitidine or ruxolitinib
  • Measured overall response rates at 6 months using International Working Group criteria
  • Overall response rate was 60% (12 of 20 patients; 95% CI, 36.1%–80.5%)
  • MDS group had a 75% response rate (3 of 4 patients; 95% CI, 31.1%–95.4%)
  • MPN group showed a 56.3% response rate (9 of 16 patients; 95% CI, 33.2%–76.9%)

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a3631a1db0793dc1a5386ddhttps://doi.org/10.1002/cncr.70459
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study2025
  2. 2Safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with myelodysplastic syndromes EB1 or EB2: A single-center, single-arm, phase ib/II trial2025
  3. 3Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study2026 · 5 citations
  4. 4Selinexor Plus Ruxolitinib in JAK Inhibitor–Naïve Myelofibrosis: Phase 3 SENTRY Trial2026 · 2 citations
  5. 5Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia.2024 · 1 citations